Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease:...

Area of Science:

• Cardiology
• Nephrology
• Biomedical Engineering

Background:

• Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, presenting complex clinical challenges.
• Advanced HF leads to electrophysiologic abnormalities, including conduction delays and ventricular arrhythmias, increasing sudden cardiac arrest risk.
• Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are established treatments for these HF complications.

Purpose of the Study:

• To review the impact of comorbid advanced HF and advanced CKD on ICD and CRT efficacy and safety.
• To synthesize current evidence regarding the management of these complex patient populations.
• To identify potential future research directions.

Main Methods:

• Literature review of studies investigating ICD/CRT in patients with coexisting advanced HF and CKD.
• Analysis of pathophysiologic changes in advanced CKD that may affect cardiovascular interventions.
• Synthesis of clinical evidence on efficacy, safety, and management strategies.

Main Results:

• Advanced CKD can alter the pharmacokinetics and pharmacodynamics of medications used in HF management.
• Cardiovascular changes associated with advanced CKD may affect device programming and lead performance for ICDs and CRT.
• Limited data exists specifically addressing the combined impact of advanced HF and CKD on ICD/CRT outcomes.

Conclusions:

• Comorbid advanced HF and advanced CKD significantly complicate the use of ICDs and CRT.
• Further research is needed to optimize device selection, programming, and patient management in this population.
• Tailored therapeutic strategies are essential for improving outcomes in patients with combined advanced HF and CKD.